Get the app
US › Healthcare

Traws Pharma Inc (TRAW)

US · Healthcare · Biotechnology

$0.37-8.39%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-3.1M
EPS
$-0.16
EPS estimate
$-0.22

EPS came in at -0.16 against a street estimate of -0.22 — a beat of 27.3%.

Key statistics

Market cap
$6.4M
Forward P/E
0.0
P/B
4.49
Book value
$0.11
EPS (TTM)
$-1.71
52-week high
$3.15
52-week low
$0.41
50-day MA
$0.54
200-day MA
$1.23
Beta
1.53

Analyst view

Analysts rate Traws Pharma Inc a hold (0 buy, 2 hold, 0 sell out of 2) with an average price target of $1.00.

Shareholding

Insiders
5.39%
Institutions
40.06%

Largest institutional holders

FundStake
Orbimed Advisors LLC7.83%
Ally Bridge Group (NY) LLC5.12%
Adage Capital Partners Gp LLC4.75%
ADAR1 Capital Management LLC3.89%
Lynx1 Capital Management, LP3.64%
Ikarian Capital, LLC3.11%
Sphera Funds Management Ltd.2.59%
Vanguard Capital Management, LLC2.15%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Traws Pharma Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.